Title: GLP-1 AND METHODS FOR TREATING DIABETES

Abstract: The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a "drug holiday". Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.
FIELD OF THE INVENTION

The present invention generally relates to a method for treating diabetes and related disorders in a mammal. In one aspect, the method involves administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect to provide a therapeutically effective amount of endogenous insulin. Subsequently, the amount of drug administered to the mammal is substantially reduced to produce a "drug holiday". Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug.

BACKGROUND


The molecular structure and function of GLP-1 has been extensively studied. GLP-1 amino acid and protein sequence has been reported for human and other mammals. Human GLP-1 is thought to have a 37 amino acid residue peptide. See eg., Heinrich, G., et al., *Endocrinol.*, 115: 2176 (1984); and Utenthal, L. O., et al., *J. Clin. Endocrinol. Metabol.*, 61:472 (1985).
Many molecular derivatives of GLP-1 have been reported. For instance, GLP-1 (7-37) is known. A variety of analogs have also been described eg., Gln⁹-GLP-1 (7-37), D-Gln⁹-GLP-1 (7-37), acetyl-Lys⁹-GLP-1 (7-37), Thr¹⁶-Lys¹⁸-GLP-1(7-37), and Lys¹⁸-GLP-1 (7-37), Gly⁶-GLP-1 (7-37), Ser⁶-GLP-1 (7-37). Other GLP-1 derivatives (sometimes called "variants") have also been reported particularly as acid addition salts, carboxylate salts, lower alkyl esters, and amides. See WO 91/11457 and Mojsov, S., *Int. J. Peptide Protein Research*, 40:333-343 (1992), and references cited therein.

Additional GLP-1 derivatives have been disclosed some of which are reported to have agonist activity. See eg., U.S. Patent Nos. 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; and 6,191,102.

Additional GLP-1 related molecules have been disclosed.


A variety of molecules related to exendin-4 and exendin-3 have been reported including analogs and derivatives. See eg., U.S. Patent No. 5,424,286; WO98/05351; WO98/30231; and published EP Application No. 99610043.4.

For instance, Larsen, B.D et al. have disclosed novel peptide agonists of GLP-1 activity. See PCT/DK00/00393.
Type II diabetes has been the subject of much investigation. The disease has been characterized by impaired glucose tolerance, hyperinsulaemia, insulin resistance, increases in glycosylated hemoglobin (HbA₁c), β-cell dysfunction and subsequent β-cell death. See generally S. N. Davis and D. K. Granner in Goodman & Gilman's *The Pharmacological Basis of Therapeutics* (9th Ed. Hardman, J.G et al. (eds) (1996)) Chapter 60, pp. 1493-1597.

In particular, infusion of GLP-1 has been reported to normalize the level of HbA₁c. There are reports that GLP-1 is further capable of enhancing the ability of β-cells to sense and respond to glucose in subjects with impaired glucose tolerance. See Byrne et al., supra.

There is general agreement that the db/db mouse is a satisfactory model of human type II diabetes. This diabetic mouse has been characterized by leptin receptor mutation leading to severe obesity, early onset of type II diabetes, hyperinsulinaemia and marked peripheral insulin resistance. Ultimately these animals develop β-cell exhaust and full insulin dependence. Thus, the clinical progression from type II to type I diabetes in db/db mice is believed to be bear relationship to human type II diabetes. See Coleman, DL (1973) *Diabetologia* 9:294; and Leiter, EH, et al. (1983) *J.Nutr.* 113:184.

Despite attempts to understand and address diabetes, there is still no cure for the disease. Reported treatment methods generally involve administration of insulin alone or in conjunction with one or more agents including oral hypoglycemic drugs. See S. N. Davis and D. Granner, supra.

Unfortunately, prior methods for preventing and treating diabetes have been problematic.
For instance, insulin therapy has been linked to several adverse reactions eg., hypoglycemia, insulin allergy and resistance, and insulin related edema. In some medical settings, these reactions can be life threatening. Contraindications and side effects abound for most conventional anti-diabetic drugs.

In addition, conventional methods for treating diabetes typically involve multidose regimens in which insulin is administered subcutaneously. The inconvenience, pain and cost associated with such methods can be considerable. Management of diabetic children and the elderly with these highly invasive and repetitive therapies can be especially difficult.

It would be useful to have methods that prevent or treat diabetes and related disorders that generally require less administration of an anti-diabetic formulation. It would be especially useful to have methods that provide a physiologically relevant amount of endogenous insulin, thereby helping to delay need to administer the anti-diabetic formulation to prevent or treat the diabetes and related disorders.

SUMMARY OF THE INVENTION

The invention generally relates to a method for preventing or treating diabetes and related disorders in a mammal. In one aspect, the method involves administering a therapeutically effective amount of glucagon like peptide (GLP-1) or related molecule having a GLP-1 like effect and then reducing that amount, often substantially, to prevent or treat the disease. Preferred practice of the invention achieves a much desired "drug holiday" during which time the mammal provides itself with a useful amount of endogenous insulin usually without further exposure to the drug. The invention has a variety of uses including helping to prevent, treat, delay onset of, or reduce symptoms associated with diabetes without continuous presence of the administered GLP-1 or a related molecule. The invention may also be used to prevent development of a failure to respond to oral diabetic compounds in some diabetic patients.
It has been discovered that it is possible to prevent or treat diabetes and related disorders by administering GLP-1 and related molecules (drugs) in a new way. More specifically, it has been found that it is not necessary to expose mammals to these drugs continuously to achieve a desired therapeutic effect. That is, it has been found that it is possible to reduce administration of the drug, sometimes substantially, over a time period referred to herein as a "drug holiday". During the drug holiday, the mammal is surprisingly able to provide itself with a useful amount of endogenous insulin. It is believed that the amount of endogenous insulin is generally sufficient to help prevent, treat, delay onset of, reduce symptoms of, or delay progression of diabetes and related disorders. Administration of GLP-1 or related molecules is not needed over this time period although after the drug holiday, drug administration can be resumed.

Practice of the invention provides important advantages.

For example, I have found that the drug holiday can provide mammals and especially human patients with much sought after relief from invasive, sometimes painful, and often repetitive and expensive therapies. Potentially serious side-effects and related complications often associated with such therapies can be reduced, delayed, or in some instances eliminated by my invention. In particular, risk of developing hypoglycemia, allergy and resistance, and edema and related insulin side effects can be sometimes be reduced or avoided by providing for at least one drug holiday in accord with this invention.

Additionally, costs associated with repeated and frequent dosing of anti-diabetic drugs (eg., GLP-1, GLP-1 related molecules, insulin) can be reduced substantially by the methods described herein.

Specific benefits accrue to human patients that have or are suspected of having diabetes or a related disorder including Type II diabetes. For example, the GLP-1 or related molecule can be administered to the patient regularly and for a time sufficient to at least maintain and, in some instances, increase endogenous insulin levels. In this embodiment, further administration of the GLP-1 or related molecule can be decreased, sometimes
substantially, to provide for the drug holiday. During this time, and without wishing to be bound to theory, it is believed that the patient is able to provide him/herself with an amount of endogenous insulin that is therapeutically relevant. That is, the amount of endogenous insulin provided is able to help the patient exert more control over undesired blood glucose fluctuations. Thus, the need to continue or even increase exposure to GLP-1 or related molecules can be avoided during the drug holiday by using my invention.

It is a further object of the invention to provide a method to prevent or treat diabetes (including related disorders) in which administration of GLP-1 or a related molecule having GLP-1 like effect is reduced during the drug holiday period. In one embodiment, administration of the drug is eliminated entirely during the drug holiday period. After or sometimes during the drug holiday period, the GLP-1 or related molecule is administered again to the mammal in an amount that is the substantially the same or different from the amount administered previously. That second drug administration can be followed by another drug holiday if desired. Thus it is a feature of the invention to provide for at least one (ie. multiple) drug holidays in which each drug holiday is preferably followed by administration of an amount of at least one of GLP-1, a GLP-1 related molecule, or another drug such as those recognized anti-diabetic agents disclosed herein such as insulin and analogues thereof.

Thus in one embodiment, the invention can be used to provide a mammal such as a human patient with a first drug holiday, after which time the GLP-1 or a related molecule having a GLP-1 like effect is administered to the patient in an amount that is preferably therapeutically effective. The method can be repeated once, twice, thrice or as often as needed to provide a therapeutic regimen that features one, two, three or more drug holidays. The invention methods can be repeated as needed eg., every day, every few days, every few weeks, every few months up to the lifetime of the mammal to prevent or treat a medical condition. Human patients who are known to have diabetes or who are suspected to be susceptible to same (eg., those with or suspected of having impaired glucose tolerance (IGT)) are expected to benefit particularly from the invention.
Accordingly, and in one aspect, the invention features a method for preventing or treating diabetes and/or a related disorder in a mammal, preferably a human patient. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one of GLP-1 and a related molecule having GLP-1 like effect in which eg., the amount and timing of administration are such as to prevent or treat the diabetes or related disorder typically without the continuous presence of the molecule in the mammal. Additional invention methods include reducing administration of the GLP-1 or related molecule below about the therapeutically effective during the drug holiday. Additional features of the drug holiday are discussed below.

Prior to induction of the drug holiday, the amount of GLP-1 or related molecule administered to the mammal is preferably, but not exclusively, one that is therapeutically effective. In one embodiment and without wishing to be bound to theory, the amount is sufficient to help the mammal maintain or even increase endogenous insulin levels (before or during the drug holiday). To begin the drug holiday, the amount of administered drug is reduced or eliminated entirely. The drug holiday period is not tied to any particular endogenous insulin level(s) or method of providing or producing that insulin in vivo so long as that during the drug holiday, the mammal is able to provide itself with some amount of useful insulin, preferably an amount that is therapeutically relevant and effective. It has been found that presence of such endogenous insulin during the drug holiday period is exceptionally useful for treating or preventing diabetes and related disorders in the mammal. Following the drug holiday period, the mammal can be subjected to additional therapy including further administration of at least one of GLP-1, a related molecule having GLP-1 like effect, and recognized anti-diabetic agents such as those mentioned herein.

Other features of the invention are described below.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is graph showing plasma insulin levels following administration of vehicle (control) and 100nmol/kg of Compound 1.
Figure 2 is a graph showing blood glucose levels (nM) after overnight fasting (17 hours).

Figure 3 is a graph showing results of an oral glucose tolerance test (OTT). Results are expressed as AUC$_{0-240}$ min (mM x min) per day.

Figure 4 is showing amounts of glycosylated hemoglobin (HbA$_{1c}$) in groups exposed to vehicle or varying concentration of Compound 1.

Figure 5 is a graph showing fasting blood glucose levels following treatment with vehicle or various Compound 1 administration strategies.

Figure 6 is a graph illustrating results from an oral glucose tolerance test (OGTT) after vehicle treatment or various Compound 1 administration strategies. Results are expressed as dAUC$_{0-240}$ min (mM x min).

Figure 7 is a graph showing pancreatic insulin mRNA levels (pg/microgram total RNA) after treatment with vehicle or various Compound 1 administration strategies.

Figure 8 is a graph showing amounts of HbA$_{1c}$ (% of total haemoglobin) in groups exposed to vehicle or various Compound 1 administration routes.

**DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**

As discussed, the invention features a method for preventing or treating diabetes in a mammal. Particular mammals that would be expected to benefit from practice of the invention include those that have, have had, are suspected of having, or are genetically or otherwise disposed to develop diabetes or a related medical condition. Particular mammals of interest include primates such as chimpanzees; rodents such as mice and rats; domesticated animals eg., rabbits, dogs, pigs, cats, sheep, goats, horses, cows and the like.
More specific mammals of interest include accepted animal models of diabetes and related disorders such as the mouse model described below. An especially preferred mammal for use with the invention is a human patient who has been diagnosed with diabetes or a related disease such as impaired glucose tolerance (IGT).

5  

As also discussed, it is an object of the invention to provide a method for treating or preventing diabetes in a mammal, including related disorders, in which the method includes administering to the mammal a therapeutically effective amount of at least one of GLP-1 and a related molecule having GLP-1 effect. Typically, the amount and timing of administration are such as to prevent or treat diabetes in the mammal without the continuous presence of the molecule. Preferably, such a method further includes reducing administration of the GLP-1 or related molecule below the therapeutically effective amount for a time conducive to producing a drug holiday. Preferred methods are generally sufficient to prevent or treat the diabetes or related disorder in the mammal.

15  

By the phrase "therapeutically relevant amount of endogenous insulin" is meant an insulin amount provided by the mammal that is at least sufficient to at least slow progression of diabetes or a related disorder in that mammal by at least about 10%, preferably at least 25% or at least about 50%. Progression of such disorders can be determined by one or a combination of recognized clinical tests such as the ability to utilize glucose or the level of glycosylated hemoglobin in the bloodstream. Preferred tests are described in more detail below. Illustrative amounts of endogenous insulin that are known in the field to be therapeutically relevant are provided below. However, it is emphasized that the invention is not tied to any particular level, amount, or production of endogenous insulin. It is recognized that the ability of a subject mammal to provide itself with at least some endogenous insulin can be manifested in an improved ability to utilize glucose eg., as determined by the tests described herein.

20  

In one embodiment of the foregoing method, and typically prior to the start of the drug holiday, administration of at least one of GLP-1 or related molecule having GLP-1 like effect is reduced during the drug holiday by at least about 50% below the therapeutic amount,
preferably at least about 90% below the therapeutic amount, and more preferably such administration is stopped during the drug holiday.

By the phrase "GLP-1 related molecule" is meant a derivative, homologue, variant or analog of GLP-1 including pharmaceutically acceptable salts and free acids thereof. Preferably, the GLP-1 related molecule is a GLP agonist. More specific GLP-1 and GLP-1 related molecules are provided below. GLP-1 analogs, derivatives, variants, precursors and homologues are all suitable for the practice of the invention as long as the active fragment that impacts endogenous insulin production is included. By "GLP-1" is meant GLP-1(7-37).

By custom, the amino-terminus of GLP-1(7-37) has been assigned number 7 and the carboxy-terminus, number 37.

The amino acid sequence of GLP-1(7-37) is well-known and has the following sequence: NH₂-His⁷-Ala-Glu-Gly¹⁰-Thr-Phe-Thr-Ser-Asp¹⁵-Val-Ser-Ser-Tyr-Leu²⁰-Glu-Gly-Gln-Ala-Ala²⁰-Lys-Glu-Phe-Ile-Ala³⁰-Trp-Leu-Val-Lys-Gly-Arg-Gly³⁷-COOH (SEQ ID NO: __)

A "GLP-1 analog" is defined as a molecule having a modification including one or more amino acid substitutions, deletions, inversions, or additions when compared with GLP-1. GLP-1 analogs include, for example, GLP-1(7-34) and GLP-1(7-35), GLP-1(7-36), Val⁸-GLP-1(7-37), Gln⁹-GLP-1(7-37), D-Gln⁹-GLP-1(7-37), Thr¹⁶-Lys¹⁸-GLP-1(7-37), and Lys¹⁸-GLP-1(7-37). Preferred GLP-1 analogs are GLP-1(7-34) and GLP-1(7-35), which are disclosed in U.S. Pat. No. 5,118,666, and also GLP-1(7-36). These compounds are the biologically processed forms of GLP-1 having insulinotropic properties. Other GLP-1 analogs are disclosed in U.S. Pat. No. 5,545,618.

By the phrase "GLP-1 derivative" is meant a molecule having the amino acid sequence of GLP-1 or of a GLP-1 analog, but additionally having at least one chemical modification of one or more of its amino acid side groups, alpha-carbon atoms, terminal amino group, or terminal carboxylic acid group. A chemical modification includes adding chemical moieties, creating new bonds, and removing chemical moieties. Modifications at
amino acid side groups include acylation of lysine epsilon-amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine. Modifications of the terminal amino include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications. A lower alkyl is a C$_1$–C$_4$ alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled protein chemist. The α-carbon of an amino acid may be mono- or di-methylated.

As discussed, the invention is compatible with use of a wide spectrum of GLP-1 analogs and derivatives. Further examples include active GLP-1 peptides, 7-34, 7-35, 7-36 and 7-37 have amino acid substitutions as positions 7-10 and/or are truncated at the C-terminus and/or contain various other amino acid substitutions in the basic peptide. Analogs having D-amino acid substitutions in the 7 and 8 positions and/or N-alkylated or N-acylated amino acids in the 7 position are particularly resistant to degradation in vivo.

See also U.S Pat. Nos. 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; 6,191,102; 6,051,689; 6,006,753; 5,846,937; 5,670,360; 5,614,492; 5,846,937; 5,545,618; 6,410,508; 6,388,053; 6,384,016; 6,329,336; 6,110,703; 5,846,747; 5,670,360; and 5,631,224 (disclosing additional GLP-1 and related molecules), the disclosures of which are incorporated by reference.

As mentioned, it is an invention object to provide subject mammals with at least one drug holiday eg., one, two, three or more of such drug holidays. It will be appreciated that the length of time associated with any particular drug holiday will vary depending on recognized parameters such as the health of the subject, sex, disease to be treated, weight, etc.

A preferred drug holiday is defined as the time interval between a first endpoint (start) and a second endpoint (finish). Typically, the first endpoint follows the reduction in administration of the GLP-1 or related molecule. The second endpoint can be readily
identified by one or a combination of standard methods. For example, such endpoints can be characterized by an inability of the subject to control fasting blood glucose (FBG) as demonstrated, for instance, by an increase in FBG of at least about 5% or 10% when compared to the time prior to the second endpoint. The second endpoint can be further identified by an unwanted increase in glycosylated hemoglobin of at least about 5% or 10%, also when compared to the interval before the second endpoint. Methods for determining FBG and glycosylated hemoglobin are known and include what is referred to herein as a standard FBG or glycosylated hemoglobin test, respectively. During a preferred drug holiday period, FBG and glycosylated hemoglobin do not increase significantly.

As stated, the length of time associated with a particular drug holiday will vary depending on recognized factors including the health of the subject, sex, disease to be treated, weight, medical history, etc. In one invention embodiment however, the drug holiday spans about one day up to about twenty five weeks eg., between from about three to four weeks. However, as mentioned above, at or near the end of a drug holiday period, the standard FBG assay will show an increase in FBG of at least about 5% or 10%.

The GLP-1 or related molecule administered in accord with this invention can be given by nearly any acceptable route including a depot formulation such as those described in US Patent Nos. 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; 6,191,102; 6,051,689; 6,006,753; 5,846,937; 5,670,360; 5,614,492; 5,846,937; 5,545,618; 6,410,508; 6,388,053; 6,384,016; 6,329,336; 6,110,703, 5,846,747; 5,670,360; and 5,631,224. Alternatively, or in addition, such drugs can be administered to the mammal bolus at least about once daily, at least once a week. Other administration routes are also envisioned including about twice daily (i.v. or subq) for between from about one to about twenty weeks.

As mentioned, it is an object of the present invention to provide at least one drug holiday eg., one, two, or three of same to prevent or treat diabetes or a related disorder. The precise number of drug holidays needed to practice the method will depend on recognized
parameters such as the health of the subject, sex, disease to be treated, etc. In one embodiment, the invention further includes administering to the mammal a second therapeutically effective amount of GLP-1 or a related molecule following the (first) drug holiday. If desired, the method can also include reducing administration of the second therapeutically effective amount of GLP-1 or related molecule for a time conducive to producing a second drug holiday. Such administration and reducing steps are repeated at least once eg., at least about 2 to about 25 times or as needed to prevent or treat the diabetes or related disorder. For instance, the invention can be practiced over the lifetime of the mammal.

As also discussed, the invention also features methods which include administering to the mammal a therapeutically effective amount of at least one of glucagon-like peptide 1 (GLP-1), or a GLP-1 related molecule to provide a therapeutically effective amount of endogenous insulin in the mammal. It is an invention objective to provide a respite (drug holiday) from conventional anti-diabetes therapies by helping to at least maintain and preferably increase endogenous insulin production in the mammal. An invention goal is to at least delay resumption of such therapy during the drug holiday period.

General methods for characterizing, diagnosing and treating human diabetes have been disclosed by S. N. Davis and D. Granner, supra; as well as references cited therein.

In one embodiment of the present invention method, the endogenous insulin production is at least about maintained in the mammal for between from about one day to about twenty five weeks. In another embodiment, administration of the GLP-1, GLP-1 related molecule is sufficient to increase the insulin production in the mammal by at least about 10% compared to a control. Preferably, the increase in endogenous insulin production is at least about 20%, more preferably at least about a 50% increase compared to the control. A preferred control is a diabetic, non-treated mammal.
Reference herein to a control mammal typically means untreated with the GLP-1 or GLP-1 related molecule. Suitable controls are mammals that may be diabetic or non-diabetic as needed to suit a particular invention use. It will be appreciated that for some invention applications, use of a control will not be needed eg., as when endogenous insulin production levels are already known.

Methods for detecting and measuring insulin levels and insulin mRNA (protein and nucleic acid levels) are routine. See generally S. N. Davis and D. Granner, supra; as well as references cited therein. Thus in one example of the invention, the method further includes monitoring at least one of endogenous insulin production and blood glucose levels. Such monitoring can, for instance, include detecting insulin mRNA in the mammal. In this embodiment, the mammal will be a non-human mammal to allow for collection and analysis of insulin producing tissue, usually a pancreatic biopsy. In human patients, less invasive monitoring of blood insulin production according to establish protocols will be helpful for some invention applications. Methods for at least detecting insulin mRNA from biological samples are known and include nucleic acid hybridization, PCR and related amplification techniques. Thus in an example of the invention, the method further includes quantitating the insulin mRNA and comparing the amount produced by the mammal to a control. Acceptable plasma insulin tests are described below.

Therapeutically relevant levels of insulin are known for a wide variety of mammals. For human patients, it has been reported that endogenous insulin circulates in the blood as a monomer at a concentration of between about 2 to about 4 ng/ml in the portal blood and in the peripheral circulation at about 0.5ng/ml or about 0.1nm. After ingestion of a meal, there is believed to be a rise in the concentration of endogenous insulin in the portal blood, followed by a smaller rise in the periphery. See S. N. Davis and D. Granner, supra.

As discussed, the invention is not tied to attaining the aforementioned levels of insulin which have been reported to be therapeutically important. Rather, there is general recognition in the field that any amount of insulin provided endogenously is relevant in most therapeutic settings. That is, it is generally preferred that a subject mammal have capacity to
provide some amount of endogenous insulin regardless of whether it achieves normal or near normal levels. Even presence of some endogenous insulin as provided by this invention will help at least slow disease progression and in some instances make it more clinically manageable.

A "therapeutically effective" amount of GLP-1 or related molecule administered in accord with this invention means restoring at least about 0.01% of the normal monomeric concentration of insulin (eg. human insulin) in the portal blood and peripheral circulation, preferably at least about 0.5% of same, more preferably at least about 5%, and even more preferably at least about 10% of those levels. Additionally preferred dosages of the GLP-1 and related molecules will further approach endogenous levels of insulin production in subject mammals eg., by at least about 50% up to 100% to 200% of same. More particular examples of such amounts can be found in one or more of the following patents: 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; 6,191,102; 6,051,689; 6,006,753; 5,846,937; 5,670,360; 5,614,492; 5,846,937; 5,545,618; 6,410,508; 6,388,053; 6,384,016; 6,329,336; 6,110,703; 5,846,747; 5,670,360; and 5,631,224.

In many embodiments, the GLP-1 or related molecule can be administered to the mammal at a dose of at least about 0.01 nmol/kg (body weight).

Thus an example of a drug holiday, in one invention embodiment, will achieve at least about 50% of the levels of insulin in the portal blood and peripheral circulation as in normal (non-diabetic) subjects, preferably at least about 80%, more preferably about 100% of same.

It will be appreciated that the baseline level of insulin production in most subject mammals can be ascertained by workers in the field. Typically normal insulin levels for most healthy human subjects are known and are understood to vary by age, sex, diet and health of particular individuals. For subjects who have or are suspected of having diabetes, that baseline can change but is ascertainable using standard methods.
In one embodiment of the method, the amount of insulin produced by the mammal is at least about 10% higher than a control as determined by a standard plasma insulin test, preferably at least about 20% higher, more preferably at least about 50% higher. A preferred control is a non-treated diabetic mammal. Conventional methods for detecting plasma insulin are disclosed below. See also S. N. Davis and D. Granner, supra.

In another embodiment, the administration of the GLP-1 or GLP-1 related molecule is at least about once daily for at least about a 24 hours. Preferably, the administration is about twice daily for between from about one to about twenty weeks. Particular amounts of the GLP-1, or GLP-1 related peptide to administer to the mammal will vary with intended use but will generally be at least about 0.01 nmol/kg (body weight), preferably at least about 0.1 nmol/kg (body weight), more preferably 1, 2, 5 or 10 nmol/kg (body weight). More particular amounts of GLP-1 or GLP-1 related molecule to use will be guided by recognized parameters including the general health of the subject, type of diabetes, sex, medical history, etc.

Use of the present invention is also fully compatible with use of exendin-4, exendin-3, as well as analogs and derivatives thereof including pharmaceutically acceptable salts of those molecules. More particular examples of such molecules have been reported in U.S. Patent No. 5,424,286; WO98/05351; WO98/30231; WO99/07404, WO 99/25727; WO 99/25728; WO 99/46283; PCT/DK00/00393; and published EP Application No. 99610043.4, the disclosures of which are incorporated by reference.

As disclosed in the PCT/DK00/00393, for instance, a particular GLP-1 analog includes a peptide X selected from the group consisting of:

(a) an exendin having at least 90% homology to exendin-4;
(b) a variant of said exendin wherein said variant comprises a modification selected from the group consisting of between one and five deletions at positions 34-39 and contains a Lys at position 40 having a lipophilic substituent; or
(c) GLP-1 (7-36) or GLP-1 (7-37) having at least one modification selected from the group consisting of:
(i) substitution of D-alanine, glycine or alpha-amino isobutyric acid for alanine at position 8 and 
(ii) a lipophilic substituent;

and Z, a peptide sequence of 4-20 amino acid units covalently bound to said variant, wherein each 
amino acid unit in said peptide sequence, Z is selected from the group consisting of Ala, Leu, Ser,
Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I
\[-\text{NH-C}(R^1)(R^2)-\text{C}(=\text{O})-\] (I)

wherein \(R^1\) and \(R^2\) are selected from the group consisting of hydrogen, \(C_{1,6}\)-alkyl, phenyl, and 
phenyl-methyl, wherein \(C_{1,6}\)-alkyl is optionally substituted with from one to three substituents 
selected from halogen, hydroxy, amino, cyano, nitro, sulfone, and carboxy, and phenyl and phenyl-
methyl is optionally substituted with from one to three substituents selected from \(C_{1,6}\)-alkyl, \(C_{2,6}\-
alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfone, and carboxy, or \(R^1\) and \(R^2\) together with the 
carbon atom to which they are bound form a cyclopetnyl, cyclohexyl, or cycloheptyl ring, e.g. \(2,4\-
diaminobutanoic acid and 2,3-diaminopropanoic acid; and a pharmaceutically acceptable salt or the 
C-terminal amide of said peptide conjugate.

More particular examples of GLP-1 and GLP-1 related molecules including analogs thereof such 
as those disclosed in the the PCT/DK00/00393 application. Such molecules include the 
following specific compounds:
des Ser \(^{39}\) -exendin-4(1-39)-Lys\(_6\)-NH\(_2\) (SEQ ID NO:____),
des Pro \(^{36}\) -exendin-4(1-39)-Lys\(_6\)-NH\(_2\) (SEQ ID NO:____),
des Ala \(^{35}\) -exendin-4(1-39)-Lys\(_6\)-NH\(_2\) (SEQ ID NO:____),
des Gly \(^{34}\) -exendin-4(1-39)-Lys\(_6\)-NH\(_2\) (SEQ ID NO:____),
des Ser \(^{39}\) -(Lys \(^{40}\) (palmitoyl))exendin-4(1-39)-Lys\(_7\)-NH\(_2\) (SEQ ID NO:____),
des Gly \(^{34}\) -(Lys \(^{40}\) (palmitoyl))exendin-4(1-39)-Lys\(_7\)-NH\(_2\) (SEQ ID NO:____),
des Ala \(^{35}\) -(Lys \(^{40}\) (palmitoyl))exendin-4(1-39)-Lys\(_7\)-NH\(_2\) (SEQ ID NO:____),
des Pro \(^{36}\) -(Lys \(^{40}\) (palmitoyl))exendin-4(1-39)-Lys\(_7\)-NH\(_2\) (SEQ ID NO:____),
Lys \(^{40}\) (palmitoyl)exendin-4(1-39)-Lys\(_7\)-NH\(_2\) (SEQ ID NO:____),
des Pro \(^{36}\), Pro \(^{37}\) -exendin-4(1-39)-Lys\(_6\)-NH\(_2\),
Lys\(_6\)-des Pro \(^{36}\), Pro \(^{37}\), Pro \(^{38}\) -exendin-4(1-39)-NH\(_2\),
Asn(Glu)\(_5\)-des Pro \(^{36}\), Pro \(^{37}\), Pro \(^{38}\) -exendin-4(1-39)-NH\(_2\),
Lys₆-des Pro³⁶, Pro³⁷, Pro³⁸-exendin-4(1-39)-Lys₆-NH₂,
Asn(Glu)₅-des Pro³⁶, Pro³⁷, Pro³⁸-exendin-4(1-39)-Lys₆-NH₂,
des Pro³⁶, Pro³⁷, Pro³⁸-exendin-4(1-39)-Lys₆-NH₂,
Gly⁸-GLP-1 (7-36)-Lys₆-NH₂ (SEQ ID NO:___),

Lys₆-Gly⁸-GLP-1 (7-36)-Lys₆-NH₂,
Lys₆-Gly⁸-GLP-1 (7-36)-NH₂,
(Gly⁸,Lys³⁷(palmitoyl)-GLP-1(7-36)(Human)-Lys₇-NH₂ (SEQ ID NO:___),
(Gly⁸,Lys²⁶(palmitoyl)-GLP-1(7-36)(Human)-Lys₆-NH₂,
Gly⁸,Lys³⁴(palmitoyl)-GLP-1(7-36)(Human)-Lys₆-NH₂,

Gly⁸-GLP-1 (7-36)-Lys₈-NH₂,
Gly⁸-GLP-1 (7-36)-Lys₁₀-NH₂,
Gly⁸-GLP-1 (7-37)-Lys₆-NH₂; and the free acid or pharmaceutically acceptable salt thereof.

Another preferred group of active compounds for use in the present invention is disclosed in WO 91/11457 and includes GLP-1(7-34), GLP-1(7-35), GLP-1(7-36), or GLP-1(7-37), or the amide form thereof, and pharmaceutically-acceptable salts thereof, having at least one modification including those shown below:

(a) substitution of glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, arginine, or D-lysine for lysine at position 26 and/or position 34; or substitution of glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, lysine, or a D-arginine for arginine at position 36;
(b) substitution of an oxidation-resistant amino acid for tryptophan at position 31;
(c) substitution of at least one of: tyrosine for valine at position 16; lysine for serine at position 18; aspartic acid for glutamic acid at position 21; serine for glycine at position 22; arginine for glutamine at position 23; arginine for alanine at position 24; and glutamine for lysine at position 26; and
(d) substitution of at least one of: glycine, serine, or cysteine for alanine at position 8; aspartic acid, glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine,
valine, isoleucine, leucine, methionine, or phenylalanine for glutamic acid at position 9; serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine for glycine at position 10; and glutamic acid for aspartic acid at position 15; and

(e) substitution of glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine, or the D- or N-acylated or alkylated form of histidine for histidine at position 7; wherein, in the substitutions is (a), (b), (d), and (e), the substituted amino acids can optionally be in the D-form and the amino acids substituted at position 7 can optionally be in the N-acylated or N-alkylated form.

See also U.S Pat Nos. 5,512,549; 5,120,712; 5,118,666; 5,120,712 and 5,523,549 for related disclosure.

As discussed, the present invention provides important methods for preventing or treating diabetes. Preferred practice involves at least maintaining endogenous insulin production in the mammal sufficient to support a drug holiday or maintaining the level of glycosylated hemoglobin sufficient to support a drug holiday. During this time, administration of an anti-diabetic formulation can be significantly reduced and sometimes avoided completely. This in one invention embodiment, the method will further include administering at least one anti-diabetic drug to the mammal. Preferably, the administration will be about below the recognized therapeutically effective amount for at least one of the drugs in the mammal. That is, the amount of at least one and preferably all of the anti-diabetic drugs given to the mammal will be below about what is accepted as the useful dose. However in other embodiments such as when addressing severe or hard to manage diabetes, it will be helpful to administer at least about at a therapeutically effective amount for at least one of the drugs in the mammal. The administration of the anti-diabetic drug can be before, during or after about the time the endogenous insulin level is at least maintained in the mammal.
In another embodiment, the method further includes discontinuing (either completely or partially) administration of at least one of the anti-diabetic drugs to the mammal. Cessation of the administration can be before, during or after about the time endogenous insulin production is at least maintained in the mammal. Preferably, the method is sufficient to prevent, treat, delay onset of, or at least alleviate symptoms associated with the diabetes in the mammal for a time after administration of the GLP-1, GLP-1 related molecule or anti-diabetic drug is discontinued.

As mentioned, practice of the invention can suitably prevent, treat, delay onset of or at least alleviate diabetic symptoms in subject mammals. In one embodiment, such benefits can be achieved in the mammal from about one day to about twenty five weeks. Of course, the length of the drug holiday period will depend on recognized parameters including the mammal of interest, the amount of GLP-1 and/or related molecule administered, and the type of diabetes, if any, to be addressed. By way of example, administration of the GLP-1 or related molecule can be repeated as needed, eg., one or more times usually after (but sometimes before or during) the drug holiday period. Thus in a particular example, the administration of the GLP-1 or related molecule is repeated one or more times after the time the endogenous insulin production at least maintained in the mammal.

Practice of the invention methods described herein is fully compatible with use of one or a combination of recognized anti-diabetic drugs including what is often referred to as a "cocktail" approach. Administration of such drugs can be before, during, or after a drug holiday although for most embodiments, the drugs will be given before or after a particular drug holiday. Use of the anti-diabetic drugs is not needed to practice the invention however it will be sometimes helpful to include such treatment in combination with use of GLP-1 and/or a related molecule having GLP-1 like effect to manage disease in a particular subject.

For instance, and in one embodiment of the method, at least one of the anti-diabetic drugs is insulin, an insulin analog; or a pharmaceutically acceptable mixture thereof. Preferred human insulin is commercially available as HUMULIN™ and NOVULIN™, for example. Additional insulins include bovine insulin, porcine insulin; or a mixture of insulins.
Sometimes use of an insulin analog will be indicated. In such embodiments, the insulin analog of choice is Lys (B28), Pro (B29) human insulin.

The invention is further compatible with use of a wide spectrum of standard anti-diabetic drugs such as those disclosed by S. N. Davis and D. Granner, supra.

In one embodiment, the anti-diabetic drug is a sulfonylurea, biguanide, thiazolidinedione, diazoxide, somatostatin, or an alpha-glucosidase inhibitor such as acarbose. Preferred sulfonylureas according to the invention can be selected from the group consisting of tolbutamide, chlorpropamide, tolazamide, acetohexamide, glyburide, glipizide, and gliclazide. A particular biguanide of interest is metformin and phenformin. Suitable thiazolidinediones include cigitazone and pioglitazone.

The present invention can be used to prevent or treat diabetes in a wide range of subject mammals. Use in a human patient that has, has had, is suspected of having, or who is predisposed to get diabetes will often be preferred. Typical diabetes will be diabetes mellitus or a related disorder. A preferred type of diabetes mellitus is selected from the group consisting of insulin-dependent diabetes mellitus (IDDM or type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, or type II diabetes). Examples of disorders related to diabetes mellitus have been described in S. N. Davis and D. Granner, supra and include, but are not limited to, impaired glucose tolerance (IGT); maturity-onset diabetes of youth (MODY); lepraheanism (insulin receptor mutation), tropical diabetes, diabetes secondary to a pancreatic disease or surgery; diabetes associated with a genetic syndrome (eg., Prader-Willi syndrome); pancreatitis; and diabetes secondary to endocrinopathies; adipositas; and metabolic syndrome (syndroma X).

The present invention is related to specific observations discussed below and in the Examples. More specifically, two long-term studies were conducted in which db/db mice were dosed daily with a particular GLP-1 receptor agonist, COMPOUND 1. The first study was initiated to explore the dose-dependent anti-diabetic effect of COMPOUND 1 after intraperitoneal (i.p.) administration twice daily for 42 days. The second study was a
conventional single-dose crossover study in which the animals were divided into two groups either dosed with COMPOUND 1 or vehicle. After 50 days, half of the vehicle-treated animals were switched to COMPOUND 1 treatment and half of the COMPOUND 1-treated animals were switched to vehicle treatment. In both studies, the progression of the type II diabetes was assessed by measuring the water- and food consumption, body weight, fasting blood glucose and glucose tolerance. To monitor the effect of COMPOUND 1 treatment on long-term control of blood glucose level, the amount of HbA1C was measured at the end of the study. Furthermore, to address whether COMPOUND 1 mediates a direct protective effect on the β-cell function, the insulin mRNA expression was measured by RT-PCR as a marker for β-cells function.

As shown below, treatment of the animals with a new GLP-1 agonist improves insulin mRNA compared to a control (no active treatment). This improvement is seen for a long time period during the compound life time. When treatment with the agonist is stopped, the relatively high insulin mRNA level remains higher for a long period of time. This sustained boost in insulin message provided by the invention provides for the drug holiday.

Particular treatment of type II diabetes with GLP-1 agonists will improve insulin mRNA. This improvement has several benefits and will last for a long time ie., days, weeks or even months in some settings. This will allow human subjects to increase dosing intervals beyond the half-life of the compound. The duration of dose intervals compared to plasma half life can be evaluated eg., by measuring plasma insulin and plasma glucose response after a standard glucose intake before and after stopping dosing with the GLP-1 agonist. If desired, glycosylated haemoglobin can also be monitored.

The GLP-1 and GLP-1 related molecules including derivatives and agonists thereof can be administered to a mammal in need of such treatment by one or several acceptable routes.
For instance, in type II diabetic patients Compound 1 can be administered subcutaneously. A wide range of formulation strategies are acceptable including use of recognized depot formulations or as water soluble formulations adapted for unitary dosing.

To better understand use of a particular GLP-1 or related molecule, subject mammals such as human patients can be divided into four groups. The study design is preferably a double blind randomized parallel study with a duration of about eight months. The three groups are dosed for one, three or six months after which dosing will be discontinued. The fourth group is treated with a placebo instead of the molecule to be tested. Fasting blood glucose, blood glucose response after a controlled oral glucose intake will be followed in parallel in all groups (particularly since it is a double blind design), in the days and weeks after stopping administration of the GLP-1 or related molecule. If desired, glycosylated haemoglobin can be followed as well. Parameters can be compared to the same parameters measured the last day before dosing with the molecule was stopped, with the other active treated groups, and with the parameters obtained in the placebo treated group. Preferred compounds such as Compound 1 have an effect on fasting blood glucose and blood glucose response after oral intake will last at least for days, preferably weeks after disappearance of the compound from the blood.

Plasma levels of the molecule to be tested can be measured using a conventional immunological approach such as RIA, Western blotting and/or ELISA.

Blood glucose and HbA1c can be measured by conventional standard bioanalytical methods.

A typically preferred administration strategy in accord with the invention is that GLP-1 and related molecules such as GLP-1 agonists (eg., Compound 1) shall be dosed only once every ten times or more of the biological half life, depending on recognized parameters such as the formulation type administered.
Progression of type II diabetes and related disorders can be monitored by one or a combination of suitable methods.

For example, type II patients are treated with at least one GLP-1 or a related molecule such a GLP-1 agonist and particularly Compound 1. Such treatment typically involves an individualized maximum tolerable dose of the compound either alone or in combination with at least one recognized anti-diabetic formulation. Examples of such formulations are disclosed herein and include oral antidiabetics such as glitazones, metformine, glucophages. It is typically useful to compare with a treatment matched patient group treated with placebo instead of the compound test.

Diagnostic tests for detecting and evaluating diabetes are known. Such tests include evaluation of peripheral neuropathy, typically by sense of vibration, retinopathy evaluated by ophtalmoscopic examination, myocardial ischaemia evaluated eg., by ECG, renal failure evaluated by proteinuria and measurements of glomerular filtration rate can be followed in an observation period of at least a few days, preferably a few weeks up to 1 to 3 years or more. The study is stopped when the compound of interest (eg., Compound 1) demonstrates a significantly slower development of secondary diabetic complications compared to non-treated patients.

Nearly any suitable statistical analysis treatment can be used. For instance, such an analysis can be made by analyzing absence of progression of the various symptoms ("survival analysis"). Suitably, at least one of peripheral neuropathy, retinopathy, myocardial ischaemia, renal loss of protein and renal insufficiency progress is significantly slower in patients receiving at least one of the GLP-1 or GLP-1 related molecule such as a GLP-1 agonist (eg., Compound 1). More specifically, treatment with the Compound 1, either alone or in combination with GLP-1 or a related molecule as described previously, will substantially reduce time of progression of type II diabetic complications.

The invention thus provides a highly useful method for providing blood glucose controlling therapy to a patient. In one embodiment, the method includes at least one and
preferably all of the following steps: (a) administering to a patient in need of treatment at least one dose of at least one GLP-1 agonist in an amount sufficient to produce a therapeutically relevant plasma concentration of endogenously made insulin, (b) reducing or eliminating administration of the GLP-1 agonist from between about one day to about twenty five weeks, and (c) optionally repeating steps a) and b) sufficient to provide the insulin to the patient (drug holiday). Such a method can be combined, if desired, with nearly any of the standard anti-diabetic strategies as disclosed herein.

The Examples below show focus on results using COMPOUND 1. It is believed that the compound is a novel, rationally designed peptide GLP-1 receptor agonist that increases insulin release and improves glucose tolerance. COMPOUND 1 was characterized in two independent long-term studies in type II diabetic db/db mice as follows. Study I: Dose-response study. COMPOUND 1 was administered twice daily for 6 weeks at doses of 0, 1, 10 or 100 nmol/kg (n=10/group). Study II: Effect of COMPOUND 1 on β-cell preservation. Four groups of animals (n=15/group) were treated with vehicle (V) or COMPOUND 1 (100 nmol/kg; i.p.; once daily) in a cross-over design (50 + 40 days; groups: V+V, V+COMPOUND 1, COMPOUND 1+V, COMPOUND 1+COMPOUND 1).

Results of these studies are discussed below. Briefly, COMPOUND 1 effectively decreased fasting blood glucose (FBG). Blood glucose after an oral glucose load was significantly lower in COMPOUND 1 treated animals compared to controls. Glycosylated hemoglobin (HbA1c) decreased dose-dependently (8.4±0.38% to 6.2±0.27%). In the V+V group, FBG, blood glucose after an oral glucose load, and HbA1c levels were significantly higher than in mice treated with COMPOUND 1 throughout. Interestingly, these effects were preserved throughout the study in db/db mice treated with COMPOUND 1 only during the first 50 days of the study. The beneficial effects of early therapy with ZP10 were associated with an increased pancreatic insulin mRNA expression relative control animals.

Unless otherwise specified, the following abbreviations have been used: DMSO Dimethylsulphoxide; FBG Fasting blood glucose; HbA1C Glycosylated hemoglobin; and OGGT Oral Glucose Tolerance Test.
EXAMPLE 1: GLP-1 and Compound 1 Bind GLP-1 Receptor

Receptor binding studies. These were carried out at MDS Panlabs, Panlabs Taiwan Ltd. In short, CHO-K1 cells harboring the human recombinant GLP-1 receptor were harvested. The membrane fraction was purified and used for binding assays. COMPOUND 1 and GLP-1 were solubilized in 0.4% DMSO. Membranes were incubated with different concentrations of test compounds covering 3 decades of concentrations in 20 mM Tris-HCl, pH 7.4, 5 mM MgCl₂, 20 mM NaCl, 1mM leupeptin, 1mM PMSF and 2% BSA for 90 min at 37°C in the presence of 0.03 nM ¹²⁵I-GLP-1 (7-36) amide. Radioactivity was measured in a γ-counter and IC₅₀-values were determined as the concentrations diminishing the specific binding (total binding minus non-specific binding in the presence of 100 nM GLP-1 (7-36) amide) by 50%.

Binding to human GLP-1 receptors. Concentrations resulting in half-maximal inhibition of binding to the human GLP-1 receptor expressed in CHO-K1 cells were 1.4 ± 0.24 nM and 5.5 ±1.3nM for COMPOUND 1 and GLP-1 (7-36) amide, respectively. Thus COMPOUND 1 was approximately 4 times more potent as an agonist than GLP-1 (7-36) amide.

Effect on plasma insulin levels. In animals pre-treated with COMPOUND 1, 100 nmol/kg i.p., the oral glucose load produced an increase in plasma insulin levels that was about twice as high as the response observed in vehicle-treated animals (P = 0.002), (Figure 1).

Figure 1 is explained in more detail as follows. It shows effect of COMPOUND 1 on release of insulin in db/db mice. Animals fasted overnight were given an oral glucose load of 1g/kg 15 min before receiving vehicle (n = 20) or 100 nmol/kg COMPOUND 1 (n = 19). Animals were bleed after 30 min and concentration of plasma insulin measured. (**: P = 0.002 vs. control animals).
Example 2- Acute Effects Of Compound 1 On Glucose Tolerance.

The animals used were *db/db* mice 11-15 weeks old (M&B, Denmark). COMPOUND 1 was administered i.p. at doses of: 0.01, 0.1, 1, 10 and 100 nmol/kg (n=4-7/group) fifteen minutes before the animals were subjected to an oral glucose load (1 g/kg). Prior to the study, the area under the blood glucose concentration curve obtained over a 240-minute period (AUC<sub>0-240</sub>; unit: mM·min) was used to stratify animals into five groups exhibiting similar glucose tolerances. Based on the dose-response relationship an ED<sub>50</sub> dose was estimated.

Example 3: Effect Of Administering Compound 1 Over 42 Days

Animals included in this study were between 6 and 10 weeks old at the beginning of the study. Four days prior to the first dosing, the animals were weighed and subjected to an overnight fast (17 hrs). The fasted animals were then subjected to an oral glucose tolerance test (OGTT). The area under the blood glucose concentration curve obtained over a 240-minute period (AUC<sub>0-240</sub>; unit: mM·min) was used to stratify animals into four groups exhibiting similar glucose tolerances. The animals were subjected to two daily i.p. doses of COMPOUND 1 at 8 am and 4 pm, respectively, for 42 days. Doses were 0 (vehicle), 1, 10 or 100 nmol/kg. The injection volume was 5 ml/kg in all groups.

*Parameters recorded in the 42 days study.* During the 42 days dosing period, body weight, food and water consumption were recorded daily. The animals over-night fasting blood glucose levels were measured on days –3, 1, 14, 41 and 43 and OGTT was performed on days –3, 1, 14 and 41 of the treatment period. On day 43 the animals were sacrificed and blood samples collected for measuring HbA<sub>1c</sub>.

*Oral Glucose Tolerance Test (OGTT).* To examine the effect of long-term treatment with COMPOUND 1 in the 42 days study, an OGTT was performed in connection with the morning dosing on days –3, 1, 14 and 41 of the 42 days dosing period. In the 90 days study an OGTT was performed in the morning on days 0, 50, 67, 78 and 90. Before the OGTT was
performed, animals were subjected to an overnight fasting (17 hours). Blood samples were taken from the tip of the tail and blood glucose measured. The whole blood glucose (mM) concentration was analyzed by the immobilized glucose oxidase method using a drop of blood (< 5 μl; Elite Autoanalyser, Bayer, Denmark) following the manufacturer's manual. Blood samples containing glucose concentrations outside the measuring range of the Elite Autoanalyser was measured by an enzymatic/photometrical method at Nova Medical Medi-Lab A/S; Denmark. In the 42 days study the animals received daily dosing immediately after the initial blood sample (fasting blood glucose level). Fifteen minutes later (t = 0) an oral dose of glucose was administered (1 g/kg, 4 ml/kg) (Sigma, St. Louis, MO, U.S.A.) dissolved in a phosphate buffer (pH = 7.40). In the 90 days study, the oral glucose load was administered immediately after initial blood sampling. In both studies BG levels were measured at t=30 min, t=60 min, t=120 min and t=240 min. The area under the curve obtained over a 240-minute period (AUC0-240; unit: mM-min) was included in the evaluation of the effect of the treatment.

Dose response effect of COMPOUND 1 in the Oral Glucose Tolerance Test. The dose-response relationship after acute i.p. administration of COMPOUND 1 demonstrated an ED50 value of 0.021 nmol/kg.

Dose-response effect of COMPOUND 1 in the 42 days study. The body weight of the animals increased between 21.5% and 26.5% during the experiment (table 2). There was no statistically significant difference in weight gain between the COMPOUND 1 and the vehicle-treated group. However, a tendency toward a slightly higher weight gain could be detected in the animals receiving 100 nmol/kg COMPOUND 1 when compared to the vehicle-treated animals. The recorded water consumption revealed an extensive water intake in the vehicle-treated animals suggesting that the animals suffer from diabetes-induced polydipsia. Moreover, the daily water intake was reduced significantly and dose dependently in the mice treated with COMPOUND 1 (table 2; p<0.001 vs. vehicle).

Table 2. Changes in body weight and water consumption at the end of the study period.
<table>
<thead>
<tr>
<th>42 days study</th>
<th>Δ Body weight (Mean ± SEM)</th>
<th>Water consumption (Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>7.5 ± 1.2</td>
<td>36.2 ± 0.78</td>
</tr>
<tr>
<td>1 nmol/kg</td>
<td>8.9 ± 1.1</td>
<td>21.7 ± 0.40*</td>
</tr>
<tr>
<td>10 nmol/kg</td>
<td>8.6 ± 1.8</td>
<td>16.2 ± 0.35*</td>
</tr>
<tr>
<td>100 nmol/kg</td>
<td>9.3 ± 1.1</td>
<td>14.0 ± 0.32*</td>
</tr>
</tbody>
</table>

*: p<0.05 vs. vehicle
<table>
<thead>
<tr>
<th>90 days study</th>
<th>Δ Body weight (Mean ± SEM)</th>
<th>Water consumption (Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle-vehicle</td>
<td>7.8 ± 1.4</td>
<td>31.7 ± 0.22</td>
</tr>
<tr>
<td>Vehicle-ZP10</td>
<td>8.5 ± 1.2</td>
<td>14.7 ± 0.13*</td>
</tr>
<tr>
<td>ZP10-vehicle</td>
<td>9.2 ± 1.6</td>
<td>21.6 ± 0.14*</td>
</tr>
<tr>
<td>ZP10-ZP10</td>
<td>9.0 ± 0.4</td>
<td>12.2 ± 0.09*</td>
</tr>
</tbody>
</table>

*: p<0.05 vs. vehicle

In the 42 days study, fasting blood glucose was measured on the day of stratification and during the study on day 1, 14, 41 and 43 (figure 2). On the day of stratification, on day 1 and day 14 no difference between the groups could be detected. However, on day 41 and 43 the fasting blood glucose level was significantly lower in the animals receiving COMPOUND 1, regardless of dose, suggesting that COMPOUND 1 elicited a marked antidiabetic effect. In order to further analyze the antihyperglycemic effect of COMPOUND 1 in both studies, the animals were subjected to an OGTT (figure 3). On the day of stratification all groups showed similar glucose tolerance. Interestingly, already after the very first dose of COMPOUND 1, glucose tolerance was improved in the ZP10 treated animals relative to vehicle-treated control animals. In vehicle-treated animals, the glucose tolerance was progressively impaired, and at the end of the study, this group showed a seven-fold decrease in their ability to respond to a glucose load when compared to the response in these animals at study start. In contrast, the COMPOUND 1 treated animals showed a clear improvement in their glucose response when compared to vehicle-treated animals. In fact, no significant change in the glucose tolerance could be detected at the end of the study when compared with the response to an OGTT on the day of stratification (figure 3).
Figure 2 is explained in more detail as follows. It shows fasting blood glucose concentrations on the day of stratification (day -3) and during treatment with COMPOUND 1 on day 1, 14, 41 and 43. Mean ± SEM. *: p<0.05 vs. fasting BG concentration in vehicle-treated mice on the same day.

Figure 3 is discussed in more detail as follows. The figure shows oral Glucose Tolerance Test (OGTT) before treatment (day -3) and on day 1, 14 and 41 of long-term treatment with COMPOUND 1. Mean ± SEM. *: p<0.05 vs. AUC_{0-240 min} on day -3 within group. §: p<0.05 vs. AUC_{0-240 min} in all three ZP10-treated groups.

As an indicator of long-term blood glucose control, HbA_{1c} was measured at the end of the study (figure 4). The level of HbA_{1c} is expressed as a percentage of the total hemoglobin concentration. These data clearly show that long-term treatment with COMPOUND 1 significantly decreases the concentration of HbA_{1c} in a dose-dependent fashion. Figure 4 shows HbA_{1c} expressed as percent of total Hgb (hemoglobin) (42 days study). Data are mean ± SEM. *: p<0.01 vs. vehicle.

Example 3: Effect Of Administering Compound 1 Over 90 Days

Three days prior to the first dosing, the animals were weighed and subjected to an overnight fast. The fasted animals were subjected to an OGTT (see below). The area under the blood glucose concentration curve obtained over a 240-minute period (AUC_{0-240}; unit: mM-min) was used to stratify animals into two groups exhibiting similar glucose tolerances. The animals were given one daily i.p. dose of COMPOUND 1, 100 nmol/kg or vehicle for a period of 50 days. The dosing was performed between 3 and 4 p.m. in order to ensure pharmacological efficacy during the period with maximal food intake, i.e. during night. After 50 days of dosing another OGTT was performed, and on this basis both the vehicle and the COMPOUND 1 treated group were re-stratified into four groups displaying similar glucose tolerances. Group 1, which initially received vehicle continued receiving vehicle. Group 2, which initially received vehicle was switched to COMPOUND 1 treatment (100 nmol/kg
i.p.). Group 3, which initially received COMPOUND 1 was changed to vehicle treatment and group 4, which initially received COMPOUND 1, was continued on COMPOUND 1 treatment (100 nmol/kg i.p.). The treatment regimen is outlined in Table 1. This dosing regimen continued for 40 days.

Table 1: Groups of treatment in the 90 days study

<table>
<thead>
<tr>
<th>Group</th>
<th>Days 1-50</th>
<th>Days 51-90</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vehicle (n=21)</td>
<td>Vehicle (n=11)</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>COMPOUND 1 (n=9* )</td>
</tr>
<tr>
<td>3</td>
<td>COMPOUND 1 (n=21)</td>
<td>Vehicle (n=11)</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>COMPOUND 1 (n=10)</td>
</tr>
</tbody>
</table>

* One animal died on Day 71

Parameters recorded in the 90 days study. During the 90 days dosing period body weight and water consumption were recorded daily. The animals fasting blood glucose levels were measured on days 44, 58, 65, 72, 86 and 91 and an OGGT was performed on days 0, 50, 67, 78 and 90 of the treatment period. On day 91 the animals were sacrificed, blood samples collected for measuring glycosylated hemoglobin, and pancreas removed for Insulin mRNA measurements.

Effect of COMPOUND 1 in the 90 days crossover study. The results from the 42 days study strongly indicated that COMPOUND 1 delayed the progression of type II diabetes in db/db mice. However, it was unclear whether COMPOUND 1 preserved the β-cell function
and thereby prevents the development of type I diabetes in these mice. Therefore, a 90 days cross-over study with a 50-day + 40-day study period was conducted. The animals were initially stratified and divided into two groups, one receiving vehicle and the other receiving 100 nmol/kg COMPOUND 1 i.p. once daily. After 50 days both groups were stratified again and divided into four groups. Group 1 continued receiving vehicle, group 2 initially received vehicle, but was changed to treatment with ZP10, group 3 initially received COMPOUND 1 and was changed to treatment with vehicle and finally group 4 continued receiving COMPOUND 1. The body weight of the animals was monitored during the study. Interestingly, during the 50 days no significant difference between the two initial groups could be detected (data not shown). However, after 90 days the body weight of group 3 and 4 was significantly higher than group 1 and 2 (table 2). This indicates that the general condition of the mice treated initially with COMPOUND 1 was better than the vehicle-treated group. The water consumption was also measured throughout the study and like in the 42 days study the water consumption was highest in the vehicle-treated groups. Interestingly, even after 40 days cessation of therapy with COMPOUND 1, the group treated with COMPOUND 1 during the first 50 days, still had lower water consumption than animals never treated with COMPOUND 1.

The fasting blood glucose was also measured during the study (figure 5). In the initial period from day 0-50, the fasting blood glucose level was significantly higher in the vehicle-treated animals than in the COMPOUND 1-treated animals. During the second treatment period, group 1 still displayed high fasting blood glucose. In contrast, group 2, 3 and 4, all had significantly lower fasting blood glucose levels throughout the 90 days study period. Group 2 exhibited an intermediate level of fasting blood glucose, but still significantly lower than group 1. These results indicate that these animals still have the ability to control their blood glucose levels after withdrawal of COMPOUND 1 for 40 days. Group 4 did not show any signs of hyperglycemia.

Figure 5 is explained in more detail as follows. It shows fasting blood glucose (FG) levels after eight hours of fasting. During Day 0-50, FG was significantly lower in animals treated with COMPOUND 1 compared with vehicle. Moreover, during the second treatment
period (Days 51-90), FG was significantly higher in mice treated with vehicle throughout relative to the other three groups. However, mice that were changed from COMPOUND 1 to vehicle had a significant higher FG level than mice treated with COMPOUND 1 throughout.

Oral glucose tolerance was measured five times during the study (figure 6). After the first 50 days the vehicle-treated group showed an impaired response to glucose whereas the glucose response of the COMPOUND 1-treated group did not deviate from the starting level. In fact, the glucose tolerances were similar in groups 2, 3 and 4 during the last 40 days. In group 3, glucose tolerance was significantly improved during the last period of the study in which the animals received treatment with COMPOUND 1 and at the end of the study, it was not different from glucose tolerances in groups 2 and 4.

Figure 6 is explained in more detail as follows. It shows oral Glucose Tolerance Test (OGTT) performed on Day 0, 50, 67, 78 and 90. Vehicle-treated db/db mice displayed progressively impaired glucose tolerance during the study. On Days 67-90, glucose tolerances were similar in the three groups of animals that were treated with COMPOUND 1 either during Day 1-50 (Group 2), Day 51-90 (Group 3), or throughout the entire study period (Group 4).

The prolonged effect on diabetic status after termination of COMPOUND 1 treatment (group 3) may reflect an improved β-cell function. In order to examine the β-cell function, we determined the expression of insulin mRNA at the end of the study (figure 7). Group 4 had increased expression of insulin mRNA compared to group 1. Intriguingly, the expression of insulin mRNA was similar in groups 3 and 4, indicating that early treatment with COMPOUND 1 prevents the deterioration of pancreatic insulin mRNA production. In order to evaluate the time-dependent changes in insulin mRNA expression following the respective treatments of groups 1-4, pancreatic insulin mRNA was also measured in a group of young untreated animals (6-10 weeks old; group 0 in figure 7). The results showed no significant difference between mRNA level in young animals and in animals treated with COMPOUND 1 for 50 or 90 days (groups 3 and 4).
Figure 7 is explained in more detail as follows. It shows a level of pancreatic insulin mRNA after the respective treatments. Mice treated with COMPOUND 1 throughout had an increased expression of insulin mRNA after 90 days of administration (Group 4) relative to vehicle-treated mice (Group 1). Interestingly, the expression of insulin mRNA was similar in mice treated with COMPOUND 1 during only the first 50 days and mice treated for 90 days, while animals in which treatment with COMPOUND 1 was not initiated until Day 50 showed an expression of insulin that was similar to the expression found in vehicle-treated mice. The level of insulin mRNA was similar in young untreated mice (group 0) and in the two groups that had received COMPOUND 1 treatment during the first part of the study (groups 3 and 4).

Finally, the HbA1c levels were measured at the end of the study (figure 8). The three groups that received COMPOUND 1 treatment had lower levels of HbA1c than animals receiving vehicle treatment throughout, but the differences did not reach statistical significance.

Figure 8 is explained in more detail as follows. It shows: HbA1c levels (% of total hemoglobin concentration) measured on the day of termination. One-way ANOVA showed no overall significant difference among groups (p = 0.22). However, Fisher's LSD test for posthoc comparisons showed that HbA1c was significantly lower in mice treated with COMPOUND 1 throughout (Group 4: 6.65±0.22%) relative to vehicle-treated mice (Group 1: 7.99±0.51%).

Example 4: Effect of COMPOUND 1 On Insulin Release In db/db Mice.

To examine the effect of COMPOUND 1 on physiological insulin release during hyperglycemia, insulin levels were determined after an oral glucose load (1 g/kg). Thirty nine overnight fasted animals entered the experiment one week after being stratified into two group after an OGTT as described above. Fifteen minutes before the animals were given an oral glucose load, each animal received vehicle or 100 nmol/kg COMPOUND 1 i.p. Thirty minutes after the glucose administration, the animals were bled by left ventricular puncture
during carbon dioxide anaesthesia. The blood was collected using a syringe mounted with a needle pre-flushed with heparine (5000 i.u./ml). The blood samples were quickly transferred into a pre-chilled test tube that contained 5 µl 0.5 M EDTA and 5 µl Trasylol® (aprotinin, 20 x 10^6 IU/ml) and centrifuged at 3000 rpm for 10 minutes at 2-4 °C. Plasma was kept cold during harvest, frozen on dry ice and stored at -80°C for later analysis of hormones. The whole blood glucose (mM) concentration was analysed as described above. Plasma concentrations of insulin were measured in samples of 10 µl plasma using a commercial enzyme immunoassay from Peninsula Laboratories Europe, LTD (ELIS7537).

Unless otherwise noted, the following materials and methods were used, as needed, in the Examples discussed above.

*Animals.* Male *db/db* mice C57BLKS/J-Leprdb/Leprdb weighing 37.3 ± 1.1 g (M&B, Ll. Skensved, Denmark) at time of inclusion were used. The mice were housed (3 mice/cage) under controlled conditions (20°C, 55-85% humidity) following a 12:12-h light/dark cycle with light on at 6 am. The animals were fed ad libitum with a standard Altromin No. 1324 diet (Chr. Petersen, Ringsted, Denmark) and had free access to domestic quality tap water. At the time of inclusion, all mice had overnight fasting (17 hrs) blood glucose (BG) levels below 10 mmol/l. No animals included in the study displayed blood glucose levels above 33 mM when subjected to a standard oral glucose load (see below).

*Water Consumption.* At the time of the morning dosing the animals were weighed, and water consumption per group was measured gravimetrically by weighing the water bottle and calculating the amount of water consumed.
Isolation of total RNA from mice pancreas. The frozen pancreatic glands were weighed and minced in a mortar under liquid nitrogen. The extraction of total RNA was conducted as described by the manufacturer of the kit (Qiagen Rneasy kit, VWR International).

First strand synthesis. 0.5-1.0 µg total RNA was used for first strand synthesis. In brief, the RNA was incubated for 10 min at 70°C and quenched on ice. The RNA was equilibrated to 42°C and mixed with 10mM dNTP, 1ul Superscript II (Life Technologies) in a final volume of 20 µl and incubated for an additional hour at 42°C. The reaction was terminated by incubation for 5 min at 94°C.

Insulin standard for quantitative PCR. One µl first strand synthesis was used for PCR with the following insulin primers: 5’-AACCCACCCAGGCTTTTGTCA; 5’-CTTCTCCACGTCCAGTTGTTC-3 The amplicon were inserted into the PCR 4-TOPO vector (invitrogen) and transformed into E.coli. The plasmids were purified and 2 µg of each were linearized with either Spe I or Not I. The linearized plasmids were in-vitro transcribed using T7 or T3 RNA polymerase. After in-vitro transcription, the template was removed by DNase treatment. Subsequently, the mixture was phenol/chloroform-extracted and precipitated. After precipitation the RNA was dissolved to 1 mg/ml in water.

Quantitative PCR. One µg of both standard and sample were subjected to first strand synthesis as described above. A dilution series of the insulin mRNA standard, together with the samples were subjected to quantitative PCR using the following probe (Mouse insulin Taqman probe, 110-138) and the above described primers:

5’-FAM-AGGCTCTCTACCTGGGTGTTGGGAGCGT- Tamra-3’

All PCR reactions were duplicates. The C_t (threshold cycle) were measured and the initial concentration of insulin mRNA was calculated according to the standard curve.
Drugs: COMPOUND 1 (H-GEGTFTSDLKQMEEEAVRLFIEWLKNNGGPSSGAPPSK
KKKKK-NH₂, Batch: ZP15.65-3A) was produced at Zealand Pharma A/S using the
Merifield technique.

Statistics: One-way classified data were analysed using one-way ANOVA and
Fisher's LSD test for post-hoc analysis. Two-way classified data were analysed using a two-
way ANOVA. Unpaired data were analysed using the Student's t-test for unpaired data.

The foregoing Examples show that COMPOUND 1 was a highly efficacious GLP-1
agonist with potent anti-diabetic efficacy. It binds to the human GLP-1 receptor with an
affinity 4 times higher than GLP-1 itself, it potentiates the secretion of insulin in response to
an oral glucose load, and normalizes glucose intolerance in diabetic db/db mice at doses in
the low nmol/kg range. Furthermore, after prolonged treatment, COMPOUND 1 increases
the insulin mRNA level, and normalizes HbA₁c levels. The Examples show that prolonged
treatment with COMPOUND 1 reduces progression of type II diabetes in db/db mice.

In this Example, all three doses of COMPOUND 1 produced a similar improvement
of glucose tolerance, fasting blood glucose and HbA₁c suggesting that COMPOUND 1
produces a maximal antidiabetic response during long-term administration of doses from 1-
100 nmol/kg i.p. The improved glucose tolerance was closely related to a decrease in daily
water intake in the COMPOUND 1 treated mice. Moreover, the daily water intake was
significantly lower in the animals receiving 100 nmol/kg than in both vehicle-treated mice
and in animals treated with only 1 nmol/kg of COMPOUND 1. These results are consistent
with the clinical finding that thirst and polydipsia are closely related to blood glucose levels
in diabetic subjects.

Animals treated with vehicle exhibited a high level of HbA₁c in contrast to the clear
dose-dependent decrease shown in the groups treated with COMPOUND 1. Without wishing
to be bound to theory, the data in this Example is consistent with COMPOUND 1 exerting a
protective effect on the pancreas (direct or indirect) that can postpone the development of severe diabetes associated with ketoacidosis and early death in \textit{db/db} mice.

This question was addressed in the Examples. Specifically, a cross-over study was designed in which animals were changed from treatment with COMPOUND 1 to vehicle. In the 42 days study, it was found that 100 nmol/kg was the most effective dose. Thus, 100 nmol/kg was used as a single daily injection in the cross-over study. The major finding of this study was that three months treatment with COMPOUND 1 prevented the progressive development of diabetes in \textit{db/db} mice. Ninety days of COMPOUND 1 treatment increased glucose tolerance, decreased fasting glucose level, decreased HbA1C, decreased water intake, and increased the expression of insulin mRNA in pancreatic \(\beta\)-cells relative to vehicle-treated control mice.

Without wishing to be bound to theory, the increased expression of pancreatic insulin mRNA suggests that the improved glucose tolerance in COMPOUND 1 treated \textit{db/db} mice was related to an improved ability to release of insulin in response to oral glucose load. This observation is supported by the Examples above, particulary the finding that plasma insulin levels increased twice as much in response to an oral glucose load in COMPOUND 1 treated mice than in untreated control animals.

Interestingly, in mice treated with COMPOUND 1 during the first 50 days of the study period, the COMPOUND 1 treatment produced a sustained improvement in glucose tolerance, decreased fasting glucose levels, lower water intake, and an elevated expression of insulin mRNA compared to vehicle-treated animals. These results demonstrate that i.p. administration of COMPOUND 1 once daily effectively prevents the progression of diabetes in \textit{db/db} mice. Without wishing to be bound by theory, the sustained effect on glucose metabolism and pancreatic expression of insulin mRNA is consistent with Compound 1 preserving \(\beta\)-cell function in diabetic \textit{db/db} mice. The persistent effect of COMPOUND 1 on insulin mRNA in the group that was shifted to vehicle (placebo) indicates a \(\beta\)-cell sparing
mechanism and/or neogenesis of β-cells from progenitor cells. There was no significant
difference between insulin mRNA level in young animals and in animals treated with
COMPOUND 1 for 50 or 90 days (groups 3 and 4) indicating that the treatment protects the
β-cells and significantly delays the progression of the type II diabetes. In mice treated with
vehicle during the first treatment period and with COMPOUND 1 from day 51 and onward,
glucose tolerance, fasting blood glucose and water intake were improved during therapy with
COMPOUND 1. Late onset of therapy with COMPOUND 1 did not substantially improve
the expression of insulin mRNA in pancreatic β-cells if treatment was initiated half-way
through the study.

The Examples also show that the protective action of COMPOUND 1 is most
effective when therapy is initiated early during the diabetic development. When therapy with
COMPOUND 1 was initiated in animals with late untreated diabetes, COMPOUND 1
improved glucose tolerance in absence of changes in the expression of insulin mRNA. The
presence of detectable insulin mRNA in vehicle-treated mice suggests that even these
severely ill animals were able to produce insulin.

The Examples further show that Compound 1 is an effective anti-diabetic compound
that prevents the progression of diabetes in db/db mice. Without wishing to be bound to
theory, the sustained effect on glucose metabolism, and pancreatic expression of insulin after
discontinuation of COMPOUND 1 treatment indicates that COMPOUND 1 preserves β-cell
function in diabetic db/db mice.

It was found that COMPOUND 1 is an effective anti-diabetic compound that prevents
the progression of diabetes in db/db mice. The sustained effect on glucose metabolism, and
pancreatic expression of insulin mRNA after discontinuation of COMPOUND 1 treatment
indicates that COMPOUND 1 preserves β-cell function in diabetic db/db mice.

The Examples can be further summarized as follows.
Compound 1 is a new and rationally designed GLP-1 agonist. COMPOUND 1 is a peptide with a high affinity for the GLP-1 receptor that increases insulin release and improves glucose tolerance. The pharmacological efficacy of COMPOUND 1 was characterized in two independent long-term studies in type 11 diabetic db/db mice lasting 6 and 12 weeks, respectively. In the 6-week study, COMPOUND 1 was administered twice daily for 6 weeks at doses of 0, 1, 10 or 100 nmol/kg (n=10/group). This study demonstrated that COMPOUND 1 effectively decreased fasting blood glucose (FBG) from 13.7±1.3 mM in control animals to 8.6±1.4 mM in COMPOUND 1 treated groups. While glucose tolerance remained unchanged during the 6-week study period for all COMPOUND 1 treated animals, the area under the curve after an oral glucose load increased 5-6 fold at the end of the study in vehicle-treated (placebo) mice. After 6 weeks, glycosylated hemoglobin (HbA1c) decreased dose-dependently from 8.4±0.38% in control animals to 6.21±0.27% in mice treated with 100 nmol/kg COMPOUND 1.

In order to assess if the long-term effects of COMPOUND 1 (100 nmol/kg; i.p.; once daily) were mediated by a Beta-cell preserving mechanism, 4 groups of animals (n=15/group) were treated with vehicle (V) or COMPOUND 1 in a cross-over design (50+40 days; groups: V+V, V+COMPOUND 1, COMPOUND 1+V, COMPOUND 1+COMPOUND 1). In the V+V group, FBG, blood glucose during an oral glucose tolerance test (OGTT), and HbA1c levels were significantly higher than in mice treated with COMPOUND 1 throughout. Interestingly, in db/db mice treated only during the first 50 days of the study, FBG, OGTT response, and HbA1c, was still lower than in V+V after 90 days. The beneficial effects of early therapy with ZP10 were associated with an increased pancreatic insulin mRNA expression relative to untreated diabetic mice (V+V: 10.4±2.2, V+COMPOUND 1: 12.7±2.4; COMPOUND 1+V: 20.9±4.1; COMPOUND 1+COMPOUND 1: 21.8±2.7 pg/mg total RNA). These studies demonstrate that COMPOUND 1 is an effective antidiabetic compound that prevents the progression of diabetes in db/db mice. Without wishing to be bound to any theory, it is believed that sustained effect on glucose metabolism, and pancreatic expression of insulin after discontinuation of COMPOUND 1 treatment indicates that COMPOUND 1 preserves β-cell function in diabetic db/db mice.

The disclosures of all references cited herein are incorporated by reference. The following references are specifically incorporated by reference.


16. USSN 60/393,917 by E. Steiness entitled "Method For Treating Diabetes and Related Disorders" as filed on July 4, 2002.

The invention has been described with reference to preferred embodiments thereof, however, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention. All documents referenced herein are incorporated by reference.
What is claimed is:

1. A method for preventing or treating diabetes in a mammal, the method comprising administering to the mammal a therapeutically effective amount of at least one GLP-1 or a related molecule having GLP-1, wherein the amount and timing of administration are such as to prevent or treat diabetes in the mammal without the continuous presence of the molecule.

2. The method of claim 1, wherein the method further comprises reducing administration of the GLP-1 or related molecule below about the therapeutically effective amount for a time conducive to producing a drug holiday, the method being sufficient to prevent or treat the diabetes or related disorder in the mammal.

3. The method of claim 2, wherein administration of the GLP-1 or related molecule is reduced during the drug holiday by at least about 50% below the therapeutic amount.

4. The method of claim 3, wherein administration of the GLP-1 or related molecule is reduced during the drug holiday by at least about 90% below the therapeutic amount.

5. The method of claim 4, wherein administration of the GLP-1 or related molecule is stopped during the drug holiday.

6. The method of claims 1-5, wherein during the drug holiday is further defined as a time interval between a first endpoint following the reduction in administering the GLP-1 or related molecule and a second endpoint.

7. The method of claim 6, wherein the second endpoint is identified by a standard FBG or glycosylated hemoglobin test.

8. The method of claims 1-7, wherein the drug holiday is for about one day to about twenty five weeks.
9. The method of claim 8, wherein the drug holiday is for between from about three to four weeks.

10. The method of claims 1-9, wherein the GLP-1 or related molecule is administered as a depot formulation.

11. The method of claims 1-10, wherein the GLP-1 or related molecule is administered to the mammal bolus at least about once daily.

12. The method of claim 11, wherein the GLP-1 or related molecule is administered to the mammal bolus at least once a week.

13. The method of claims 1-12, wherein the administration of the GLP-1 or related molecule is about twice daily (i.v. or subQ) for between from about one to about twenty weeks.

14. The method of the claim 1, wherein the method further comprises administering to the mammal a second therapeutically effective amount of GLP-1 or a related molecule following the drug holiday.

15. The method of claim 14, wherein the method further comprises reducing administration of the second therapeutically effective amount of GLP-1 or related molecule for a time conducive to producing a second drug holiday.

16. The method of claim 1 or 15, wherein the administration and reducing steps are repeated at least once.

17. The method of claim 16, wherein the administration and reducing steps are repeated at least about 2 to about 25 times.

18. The method of claim 17, wherein the administration and reducing steps are repeated as needed to prevent or treat the diabetes or related disorder.
19. The method of claim 18, wherein the method is practiced over the lifetime of the mammal.

20. The method of claims 1-19, wherein the GLP-1 or related molecule is administered to the mammal at a dose of at least about 0.01 nmol/kg (body weight).

21. The method of claims 1-20, wherein the GLP-1 or related molecule has been disclosed in U.S Pat. Nos. 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; 6,191,102; 6,051,689; 6,006,753; 5,846,937; 5,670,360; 5,614,492; 5,846,937; 5,545,618; 6,410,508; 6,388,053; 6,384,016; 6,329,336; 6,110,703; 5,846,747; 5,670,360; or 5,631,224.

22. The method of claims 1-21, wherein the GLP-1 or related molecule is exendin-4, exendin-3; or an analog or derivative thereof.


24. The method of claims 1-23, wherein the method further comprises administering at least one anti-diabetic drug to the mammal.

25. The method of claim 24, wherein the administration is below about a therapeutically effective amount for at least one of the drugs in the mammal.

26. The method of claim 24, wherein the administration is at least about at a therapeutically effective amount for at least one of the drugs in the mammal.

27. The method of claims 1-26, wherein administration of the anti-diabetic drug is before or after the drug holiday.
28. The method of claims 1-27, wherein at least one of the anti-diabetic drugs is insulin, an insulin analog; or a pharmaceutically acceptable mixture thereof.

29. The method of claim 28, wherein the insulin is human insulin, bovine insulin, porcine insulin; or a mixture thereof.

30. The method of claims 1-29, wherein the insulin analog is Lys (B28), Pro (B29) human insulin.

31. The method of claims 1-30, wherein the anti-diabetic drug is a sulfonylurea, biguanide, thiazolidinedione, diazoxide, somatostatin, or an alpha-glucosidase inhibitor.

32. The method of claim 31, wherein the sulfonylurea is selected from the group consisting of tolbutamide, chlorpropamide, tolaamide, acetohexamide, glyburide, glipizide, and gliclazide.

33. The method of claim 31, wherein the biguanide is metformin or phenformin.

34. The method of claim 31, wherein the thiazolidinedione is ciglitazone or pioglitazone.

35. The method of claim 31, wherein the alpha-glucosidase inhibitor is acarbose.

36. The method of claims 1-35, wherein the mammal is a human subject who has or is suspected of having diabetes mellitus or a related disorder.

37. The method of claim 36, wherein the diabetes mellitus is selected from the group consisting of insulin-dependent diabetes mellitus (IDDM or type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, or type II diabetes).

38. The method of claim 36, wherein the human subject suspected of having the diabetes mellitus is genetically pre-disposed to develop the disease.
39. The method of claim 36, wherein the disorder related to diabetes mellitus is selected from the group consisting of impaired glucose tolerance (IGT), maturity-onset diabetes of youth (MODY); leprechaunism (insulin receptor mutation), tropical diabetes, diabetes secondary to a pancreatic disease or surgery; diabetes associated with a genetic syndrome (eg., Prader-Willi syndrome); pancreatitis; and diabetes secondary to endocrinopathies; adipositas; and metabolic syndrome (syndroma X).

40. Use of at least one GLP-1 or a related molecule having GLP-1 effect for the manufacture of a medicament for preventing or treating diabetes in a mammal, wherein the amount and timing of administration of said medicament are such as to prevent or treat diabetes in the mammal without the continuous presence of said molecule.

41. The use according to claim 40, further comprising reducing administration of the GLP-1 or related molecule below about the therapeutically effective amount for a time conducive to producing a drug holiday.

42. The use according to claim 41, wherein administration of the GLP-1 or related molecule is reduced during the drug holiday by at least about 50% below the therapeutic amount.

43. The use according to claim 42, wherein administration of the GLP-1 or related molecule is reduced during the drug holiday by at least about 90% below the therapeutic amount.

44. The use according to claim 43, wherein administration of the GLP-1 or related molecule is stopped during the drug holiday.

45. The use according to claims 40-44, wherein during the drug holiday is further defined as a time interval between a first endpoint following the reduction in administering the GLP-1 or related molecule and a second endpoint.
46. The use according to claim 45, wherein the second endpoint is identified by a standard FBG or glycosylated hemoglobin test.

47. The use according to claims 40-46, wherein the drug holiday is for about one day to about twenty-five weeks.

48. The use according to claim 47, wherein the drug holiday is for between from about three to four weeks.

49. The use according to claims 40-48, wherein the GLP-1 or related molecule is administered as a depot formulation.

50. The use according to claims 40-49, wherein the GLP-1 or related molecule is administered to the mammal bolus at least about once daily.

51. The use according to claim 50, wherein the GLP-1 or related molecule is administered to the mammal bolus at least once a week.

52. The use according to claims 40-51, wherein the administration of the GLP-1 or related molecule is about twice daily (i.v. or subQ) for between from about one to about twenty weeks.

53. The use according to claim 40, further comprising administering to the mammal a second therapeutically effective amount of GLP-1 or a related molecule following the drug holiday.

54. The use according to claim 53, further comprising reducing administration of the second therapeutically effective amount of GLP-1 or related molecule for a time conducive to producing a second drug holiday.

55. The use according to claim 40 or 54, wherein the administration and reducing steps are repeated at least once.
56. The use according to claim 55, wherein the administration and reducing steps are repeated at least about 2 to about 25 times.

57. The method of claim 56, wherein the administration and reducing steps are repeated as needed to prevent or treat the diabetes or related disorder.

58. The use according to claim 57, wherein the use is practiced over the lifetime of the mammal.

59. The use according to claims 40-58, wherein the GLP-1 or related molecule is administered to the mammal at a dose of at least about 0.01 nmol/kg (body weight).

60. The use according to claims 40-59, wherein the GLP-1 or related molecule has been disclosed in U.S. Pat. Nos. 6,358,924; 6,344,180; 6,284,725; 6,277,819; 6,271,241; 6,268,343; 6,191,102; 6,051,689; 6,006,753; 5,846,937; 5,670,360; 5,614,492; 5,846,937; 5,545,618; 6,410,508; 6,388,053; 6,384,016; 6,329,336; 6,110,703; 5,846,747; 5,670,360; or 5,631,224.

61. The use according to claims 40-62, wherein the GLP-1 or related molecule is exendin-4, exendin-3; or an analog or derivative thereof.

62. The use according to claim 61, wherein the exendin-4, exendin-3; or derivative thereof has been disclosed in U.S. Patent No. 5,424,286; WO98/05351; WO98/30231; WO99/07404, WO 99/25727; WO 99/25728; WO 99/46283; PCT/DK00/00393; or published EP Application No. 99610043.4.

63. The use according to claims 40-62, wherein the method further comprises administering at least one anti-diabetic drug to the mammal.

64. The use according to claim 63, wherein the administration is below about a therapeutically effective amount for at least one of the drugs in the mammal.
65. The use according to claim 63, wherein the administration is at least about at a therapeutically effective amount for at least one of the drugs in the mammal.

66. The use according to claims 40-65, wherein administration of the anti-diabetic drug is before or after the drug holiday.

67. The use according to claims 40-66, wherein at least one of the anti-diabetic drugs is insulin, an insulin analog; or a pharmaceutically acceptable mixture thereof.

68. The use according to claim 67, wherein the insulin is human insulin, bovine insulin, porcine insulin; or a mixture thereof.

69. The use according to claims 40-68, wherein the insulin analog is Lys (B28), Pro (B29) human insulin.

70. The use according to claims 40-69, wherein the anti-diabetic drug is a sulfonylurea, biguanide, thiazolidinedione, diazoxide, somatostatin, or an alpha-glucosidase inhibitor.

71. The use according to claim 70, wherein the sulfonylurea is selected from the group consisting of tolbutamide, chlorpropamide, tolazamide, acetohexamide, glyburide, glipizide, and gliclazide.

72. The use according to claim 70, wherein the biguanide is metformin or phenformin.

73. The use according to claim 70, wherein the thiazolidinedione is cigitazone or pioglitazone.

74. The use according to claim 70, wherein the alpha-glucosidase inhibitor is acarbose.

75. The use according to claims 40-74, wherein the mammal is a human subject who has or is suspected of having diabetes mellitus or a related disorder.
76. The use according to claim 75, wherein the diabetes mellitus is selected from the group consisting of insulin-dependent diabetes mellitus (IDDM or type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, or type II diabetes).

77. The use according to claim 75, wherein the human subject suspected of having the diabetes mellitus is genetically pre-disposed to develop the disease.

78. The use according to claim 75, wherein the disorder related to diabetes mellitus is selected from the group consisting of impaired glucose tolerance (IGT), maturity-onset diabetes of youth (MODY); leprechaunism (insulin receptor mutation), tropical diabetes, diabetes secondary to a pancreatic disease or surgery; diabetes associated with a genetic syndrome (e.g., Prader-Willi syndrome); pancreatitis; and diabetes secondary to endocrinopathies; adipitas; and metabolic syndrome (syndrome X).
Figure 2

Blood Glucose Level after overnight fasting (17 h)

- Vehicle
- 1 mmol/kg
- 10 mmol/kg
- 100 mmol/kg

[Graph showing glucose levels over time for different treatments]

2/8
Figure 3

Oral Glucose Tolerance Test (OGTT)

![Graph showing AUC (area under the curve) over time for different glucose tolerance test conditions. The y-axis represents AUC (mM x min) ranging from 0 to 3500, and the x-axis represents days from -3 to 41. Different markers and lines indicate different concentrations (Vehicle, 1 nmol/kg, 10 nmol/kg, 100 nmol/kg) with statistical significances indicated by asterisks.]
Figure 4

HbA1C
Day 43

HbA1C (% of total Hb)

Vehicle 1 nmol/kg 10 nmol/kg 100 nmol/kg

Groups

4/8
Figure 5

Fasting Blood Glucose

Day of treatment

5/8
Figure 6

Oral Glucose Tolerance Test (OGTT)

![Graph showing changes in dAUC over time.](image)

- ○ Vehicle throughout study
- △ Vehicle day 1-50, ZP10A day 51-90
- ▲ ZP10A day 1-50, vehicle day 51-90
- ● ZP10A throughout study

Day of treatment

6/8
Figure 7

Pancreatic Insulin mRNA

Graph showing insulin mRNA levels in different groups. The x-axis represents groups (0, 1, 2, 3, 4), and the y-axis represents insulin mRNA levels (pg/μg total RNA) ranging from 0 to 30.

Key:
- Vehicle throughout study
- Vehicle day 1-50, ZP10A day 51-90
- ZP10A day 1-50, vehicle day 51-90
- ZP10A throughout study
- Young untreated

7/8
Figure 8

![HbA1c Graph]

8/8

SUBSTITUTE SHEET (RULE 26)
### INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

IPCs: C07K14/575, C07K14/605, A61K38/26, A61P3/10, A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC.

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols):
IPC 7 C07K A61K C07D C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:

Electronic database consulted during the international search (name of data base and, where practical, search terms used):
EPO-Internal, WPI Data, CHEM ABS Data, EMBASE.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 99 43708 A (MADSEN KJELD; NOVONORDISK AS (DK); HUUSFELDT PER OLAF (DK); KNUDSE) 2 September 1999 (1999-09-02) claim 89</td>
<td>1-78</td>
</tr>
<tr>
<td>X</td>
<td>WO 01 32158 A (SQUIBB BRISTOL MYERS CO; PIPER BETH ANNE (US)) 10 May 2001 (2001-05-10) claim 69</td>
<td>1-78</td>
</tr>
<tr>
<td>X</td>
<td>US 6 358 924 B1 (HOFFMANN JAMES ARTHUR) 19 March 2002 (2002-03-19) claim 11</td>
<td>1-78</td>
</tr>
<tr>
<td>X</td>
<td>WO 01 04156 A (LARSEN BJARNE DUE; NEVE SOEREN (DK); MIKKELSEN JENS DAMGAARD (DK)) 18 January 2001 (2001-01-18) claims 1-48</td>
<td>1-78</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

**Further Information**

- **A** document defining the general state of the art which is not considered to be of particular relevance.
- **E** earlier document but published on or after the international filing date.
- **L** later document published after the international filing date and not in conflict with the application but cited to understand the principle or theory underlying the invention.
- **O** document relating to an oral disclosure, use, exhibition or other means.
- **P** document published prior to the international filing date but later than the priority date claimed.

Data of the actual completion of the international search: 30 September 2003

Date of mailing of the international search report: 22.10.2003

Name and mailing address of the ISA: European Patent Office, P.B. 5818 Patentcitaten 2 NL - 2280 HV Rijswijk Tel. +31-70 440 40 40, Tx. 31 651 epos nl, Fax: +31-70 440-5016

Authorized officer: FERNANDO FARIETA /EO

Form: PCT/ISA/18 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>ANDREW A. YOUNG ET AL: &quot;Studies in Obese Diabetic (ob/ob, db/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatta)&quot; DIABETES, vol. 48, May 1999 (1999-05), pages 1026-1034, XP002256109 figures 1,2</td>
<td>1-78</td>
</tr>
<tr>
<td>X</td>
<td>LISA JUNTTI-BERGGREN ET AL: &quot;The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients&quot; DIABETES CARE, vol. 19, no. 11, November 1996 (1996-11), pages 1200-1206, XP002256110 figure 1</td>
<td>1-78</td>
</tr>
<tr>
<td>X</td>
<td>DAVID G. PARKES ET AL: &quot;Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 In Vivo and In Vitro&quot; METABOLISM, vol. 50, no. 5, May 2001 (2001-05), pages 583-589, XP002256111 figure 2</td>
<td>1-78</td>
</tr>
<tr>
<td>A</td>
<td>RÉMY BURCELIN ET AL: &quot;Long-Lasting Antidiabetic Effect of a Dipeptidyl Peptidase IV-Resistant Analog of Glucagon-Like Peptide-1&quot; METABOLISM, vol. 48, no. 2, February 1999 (1999-02), pages 252-258, XP002256112 figures 1,2</td>
<td>1-78</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>A</td>
<td>DORIS A. STOFFERS ET AL: &quot;Insulinotropic Glucagon-Like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein IDX-1 and Increase Islet Size in Mouse Pancreas&quot;</td>
<td>1-78</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 1-78
   because they relate to subject matter not required to be searched by this Authority, namely:
   see FURTHER INFORMATION sheet PCT/ISA/210

2. \( \square \) Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. \( \square \) Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. \( \square \) As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. \( \square \) As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment.
   of any additional fee.

3. \( \square \) As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. \( \square \) No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- \( \square \) The additional search fees were accompanied by the applicant's protest.
- \( \square \) No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)
Continuation of Box I.1

Claims Nos.: 1-78

Claims 1-78 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (PCT Rule 39.1(iv)).

The wording "drug holiday" is defined (Description, page 11, lines 29-30) as the time interval between a first endpoint (start) and a second endpoint (finish). Claim 1 seems to comprise such definition by the wording "...without the continuous presence of the molecule".

According to W099/43708, the use of GLP-1 derivatives and exendin for the treatment of diabetes is known (See claim 89- W099/43708). Therefore, the term "drug holiday" appears to be unclear if it referring to the dose administrated, in that case the claims 40-78 comprise also therapy or diagnostic methods practiced on the human or animal body (PCT Rule 39.1(iv)).

Consequently, a search has been carried out for on the alleged effects of the compounds or compositions for GLP-1 derivatives and exendin. Further, the search has covered the general aspects of the invention to some extent, although it lacks the necessary precision in the definition of the subject matter due to the large quantity of material known within GLP-1 and exendin derivatives.

The search for the general concept of GLP-1 derivatives and exendin will retrieve a pertinent document only if this concept is described in general terms in a reference. Specific solutions previously known and falling under the general concept - but failing to mention this fact - are likely not to be revealed in such a search.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9943708 A</td>
<td>02-09-1999</td>
<td>AU 3247799 A</td>
<td>15-09-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9943708 A1</td>
<td>02-09-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1056775 A1</td>
<td>06-12-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003522099 T</td>
<td>22-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6268343 B1</td>
<td>31-07-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2001011071 A1</td>
<td>02-08-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2001047684 A1</td>
<td>29-11-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 99901571 A</td>
<td>02-09-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1082661 A</td>
<td>14-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 8022900 A</td>
<td>14-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 106732 A</td>
<td>28-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 106733 A</td>
<td>28-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0015294 A</td>
<td>15-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0015295 A</td>
<td>24-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2389928 A1</td>
<td>10-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2389931 A1</td>
<td>10-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1414862 T</td>
<td>30-04-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 20021547 A3</td>
<td>15-01-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1253944 A2</td>
<td>06-11-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1229918 A2</td>
<td>14-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0300218 A2</td>
<td>28-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0300642 A2</td>
<td>28-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003519621 T</td>
<td>24-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LT 2002062 A ,B</td>
<td>25-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LT 2002063 A ,B</td>
<td>25-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20022085 A</td>
<td>24-06-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20022087 A</td>
<td>24-06-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 4992002 A3</td>
<td>01-04-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0132157 A2</td>
<td>10-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0132158 A2</td>
<td>10-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002183345 A1</td>
<td>05-12-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2312190 A1</td>
<td>17-06-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1649486 A1</td>
<td>08-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001525371 T</td>
<td>11-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002123466 A1</td>
<td>05-09-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9929336 A1</td>
<td>17-06-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 242267 T</td>
<td>15-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 5966000 A</td>
<td>30-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2378431 A1</td>
<td>18-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1376166 T</td>
<td>23-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60063182 D1</td>
<td>16-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0104156 A1</td>
<td>18-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1329456 A2</td>
<td>23-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003505347 T</td>
<td>12-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 517012 A</td>
<td>28-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6526486 B1</td>
<td>09-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1076066 A1</td>
<td>14-02-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1329458 A2</td>
<td>23-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 242267 T</td>
<td>15-06-2003</td>
</tr>
</tbody>
</table>

Form PCT/ISA/10 (patent family zone) (July 1982)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 1329458 A</td>
<td></td>
<td>AU 5966000 A</td>
<td>30-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2378431 A1</td>
<td>18-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1376166 T</td>
<td>23-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60003182 D1</td>
<td>10-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 6104156 A1</td>
<td>18-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003505347 T</td>
<td>12-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 517012 A</td>
<td>28-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6528486 B1</td>
<td>04-03-2003</td>
</tr>
<tr>
<td>US 6344180 B1 05-02-2002</td>
<td></td>
<td>AU 5489400 A</td>
<td>02-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2376473 A1</td>
<td>21-12-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1185308 A2</td>
<td>13-03-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003502344 T</td>
<td>21-01-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0077939 A2</td>
<td>21-12-2000</td>
</tr>
</tbody>
</table>